Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Salma Assil"'
Autor:
Salma Assil, Thomas P. Buters, Pieter W. Hameeteman, Charlie Hallard, Nicoline Treijtel, Tessa Niemeyer – Van der Kolk, Marieke L. de Kam, Edwin F. I. I. I. Florencia, Errol P. Prens, Martijn B. A. van Doorn, Robert Rissmann, Naomi B. Klarenbeek, Manon A. A. Jansen, Matthijs Moerland
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Imiquimod (IMQ) is a topical agent that induces local inflammation via the Toll-like receptor 7 pathway. Recently, an IMQ-driven skin inflammation model was developed in healthy volunteers for proof-of-pharmacology trials. The aim of this study was t
Externí odkaz:
https://doaj.org/article/f03a8555dda44e0c8f9b4a37d47243ce
Autor:
Tessa Niemeyer‐van der Kolk, Salma Assil, Thomas P. Buters, Melanie Rijsbergen, Erica S. Klaassen, Gary Feiss, Edwin Florencia, Errol P. Prens, Jacobus Burggraaf, Martijn B.A. vanDoorn, Robert Rissmann, Matthijs Moerland
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 3, Pp 573-579 (2020)
Omiganan (OMN; a synthetic cationic peptide) and imiquimod (IMQ; a TLR7 agonist) have synergistic effects on interferon responses in vitro. The objective of this study was to translate this to a human model for proof‐of‐concept, and to explore th
Externí odkaz:
https://doaj.org/article/42391760444a4082ab3df6cc9a119ef1
Autor:
Thomas P. Buters, Matthijs Moerland, Errol P. Prens, Martijn B. A. van Doorn, G. Feiss, M. Rijsbergen, Erica S. Klaassen, Tessa Niemeyer-van der Kolk, Robert Rissmann, Salma Assil, Jacobus Burggraaf, Edwin Florencia
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 3, Pp 573-579 (2020)
Clinical and Translational Science, 13(3), 573-579. WILEY
Clinical and Translational Science, 13(3), 573-579. Wiley-Blackwell Publishing Ltd
Clinical and Translational Science
Clinical and Translational Science, 13(3), 573-579. WILEY
Clinical and Translational Science, 13(3), 573-579. Wiley-Blackwell Publishing Ltd
Clinical and Translational Science
Omiganan (OMN; a synthetic cationic peptide) and imiquimod (IMQ; a TLR7 agonist) have synergistic effects on interferon responses in vitro. The objective of this study was to translate this to a human model for proof-of-concept, and to explore the po
Autor:
Rianne Rijneveld, Matthijs Moerland, Errol P. Prens, Salma Assil, Martijn B. A. van Doorn, G. Feiss, Erica S. Klaassen, Edwin Florencia, Jacobus Burggraaf, Tessa Niemeyer-van der Kolk, Robert Rissmann
Publikováno v:
Clinical and Translational Science
Imiquimod (IMQ) is often used as a topical challenge agent to provoke local skin inflammation. The objective of this study was to develop and refine a rapid, temporary, and reversible human skin inflammation model with IMQ for application in clinical